| 11/16/2026 6:45 AM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/13/2026 4:06 PM | Plus Therapeutics (1095981) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/13/2026 3:51 PM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/12/2026 7:30 AM | ANDREWS RONALD ASBURY (1299153) Reporting Plus Therapeutics (1095981) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/02/2026 6:30 AM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/01/2026 7:00 AM | Plus Therapeutics (1095981) Issuer Guse Kyle (1566618) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2026 7:00 AM | Plus Therapeutics (1095981) Issuer HEDRICK MARC H (1203672) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2026 7:00 AM | ANDREWS RONALD ASBURY (1299153) Reporting Plus Therapeutics (1095981) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2026 7:00 AM | Plus Therapeutics (1095981) Issuer Sims Andrew John Hugh MacIntyre (1802687) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2026 7:00 AM | Plus Therapeutics (1095981) Issuer Clowes Howard (1806992) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2026 7:00 AM | Plus Therapeutics (1095981) Issuer Hawkins Richard J (1307632) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for PSTV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 10/01/2026 7:00 AM | Plus Therapeutics (1095981) Issuer van Es-Johansson An (1795902) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/18/2026 4:23 PM | Plus Therapeutics (1095981) Filer | Form D Notice of Exempt Offering of Securities | |
| 09/10/2026 7:01 AM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/04/2026 3:30 PM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/18/2026 3:30 PM | Plus Therapeutics (1095981) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 06/07/2026 11:15 PM | Plus Therapeutics (1095981) Filer | Form EFFECT | |
| 06/05/2026 6:31 AM | Plus Therapeutics (1095981) Filer | Form S-3/A | |
| 06/01/2026 7:58 PM | Plus Therapeutics (1095981) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 05/15/2026 3:46 PM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/15/2026 11:21 AM | CVI Investments, Inc. (1649553) Filed by Plus Therapeutics (1095981) Subject | Form SCHEDULE 13G/A | |
| 05/15/2026 5:45 AM | HIGHBRIDGE CAPITAL MANAGEMENT LLC (919185) Filed by Plus Therapeutics (1095981) Subject | Form SCHEDULE 13G | |
| 04/22/2026 4:00 PM | Daniels Eric Joseph (1892943) Reporting Plus Therapeutics (1095981) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/21/2026 4:00 PM | Daniels Eric Joseph (1892943) Reporting Plus Therapeutics (1095981) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/21/2026 7:30 AM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/09/2026 7:01 AM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/08/2026 6:30 AM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/01/2026 6:30 AM | HEDRICK MARC H (1203672) Reporting Plus Therapeutics (1095981) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/01/2026 6:30 AM | Plus Therapeutics (1095981) Issuer Sims Andrew John Hugh MacIntyre (1802687) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 3:30 PM | Plus Therapeutics (1095981) Filer | Form DEFA14A | |
| 03/31/2026 3:20 PM | Plus Therapeutics (1095981) Filer | Form DEF 14A | |
| 03/26/2026 7:33 AM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/12/2026 3:29 PM | Plus Therapeutics (1095981) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/06/2026 3:05 PM | Plus Therapeutics (1095981) Filer | Form RW | |
| 02/13/2026 3:09 PM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/22/2026 9:02 AM | CVI Investments, Inc. (1649553) Filed by Plus Therapeutics (1095981) Subject | Form SCHEDULE 13G | |
| 01/22/2026 6:30 AM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/14/2026 3:02 PM | Plus Therapeutics (1095981) Filer | Form 424B4 | |
| 01/13/2026 11:15 PM | Plus Therapeutics (1095981) Filer | Form EFFECT | |
| 01/13/2026 8:48 PM | Plus Therapeutics (1095981) Filer | Form S-1MEF | |
| 01/09/2026 3:10 PM | Plus Therapeutics (1095981) Filer | Form S-1 Registration statement under Securities Act of 1933 | |
A Nasdaq drone company just landed a deal with a Philippine billionaire's group (Ad) A Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billionaire Enrique Razon Jr.'s business empire. The Razon Group spans ports, energy, mining, utilities and infrastructure, and its affiliated port operator generated over $3.2 billion in 2025 revenue.
The deal lays the groundwork for drone manufacturing in the Philippines, with potential expansion across Southeast Asia. The company was also selected for a five-year Canadian Armed Forces contract covering 100 systems, with options for up to 4,900 more.
It supplies the U.S. Army, holds a U.S. Air Force Special Operations Command contract, and recently announced a $10 million strategic investment from Unusual Machines. See why this Nasdaq drone company is attracting attention and what comes next. |
| 01/02/2026 3:30 PM | Plus Therapeutics (1095981) Issuer Sims Andrew John Hugh MacIntyre (1802687) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/02/2026 3:30 PM | HEDRICK MARC H (1203672) Reporting Plus Therapeutics (1095981) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/17/2025 6:35 AM | Plus Therapeutics (1095981) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |